ZA941812B - Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 - Google Patents

Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2

Info

Publication number
ZA941812B
ZA941812B ZA941812A ZA941812A ZA941812B ZA 941812 B ZA941812 B ZA 941812B ZA 941812 A ZA941812 A ZA 941812A ZA 941812 A ZA941812 A ZA 941812A ZA 941812 B ZA941812 B ZA 941812B
Authority
ZA
South Africa
Prior art keywords
tumor rejection
rejection antigen
hla
nucleic acid
acid sequence
Prior art date
Application number
ZA941812A
Other languages
English (en)
Inventor
Vincent Brichard
Van Aline Pel
Catia Traversari
Thomas Wolfel
De Etienne Plaen
Thierry Boon-Falleur
Original Assignee
Ludwig Inst Cancer Res
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ludwig Inst Cancer Res filed Critical Ludwig Inst Cancer Res
Publication of ZA941812B publication Critical patent/ZA941812B/xx

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K14/00—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof
    • C07K14/435—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans
    • C07K14/46—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates
    • C07K14/47—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals
    • C07K14/4701—Peptides having more than 20 amino acids; Gastrins; Somatostatins; Melanotropins; Derivatives thereof from animals; from humans from vertebrates from mammals not used
    • C07K14/4748—Tumour specific antigens; Tumour rejection antigen precursors [TRAP], e.g. MAGE
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/574—Immunoassay; Biospecific binding assay; Materials therefor for cancer
    • G01N33/57484—Immunoassay; Biospecific binding assay; Materials therefor for cancer involving compounds serving as markers for tumor, cancer, neoplasia, e.g. cellular determinants, receptors, heat shock/stress proteins, A-protein, oligosaccharides, metabolites
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Engineering & Computer Science (AREA)
  • Molecular Biology (AREA)
  • General Health & Medical Sciences (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Biomedical Technology (AREA)
  • Medicinal Chemistry (AREA)
  • Cell Biology (AREA)
  • Organic Chemistry (AREA)
  • Food Science & Technology (AREA)
  • Gastroenterology & Hepatology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Oncology (AREA)
  • Toxicology (AREA)
  • Genetics & Genomics (AREA)
  • Biotechnology (AREA)
  • Zoology (AREA)
  • Microbiology (AREA)
  • Analytical Chemistry (AREA)
  • Hospice & Palliative Care (AREA)
  • Physics & Mathematics (AREA)
  • Biophysics (AREA)
  • General Physics & Mathematics (AREA)
  • Pathology (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicines Containing Material From Animals Or Micro-Organisms (AREA)
  • Measuring Or Testing Involving Enzymes Or Micro-Organisms (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
ZA941812A 1993-03-18 1994-03-15 Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2 ZA941812B (en)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
US08/032,978 US5620886A (en) 1993-03-18 1993-03-18 Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2

Publications (1)

Publication Number Publication Date
ZA941812B true ZA941812B (en) 1994-10-13

Family

ID=21867896

Family Applications (1)

Application Number Title Priority Date Filing Date
ZA941812A ZA941812B (en) 1993-03-18 1994-03-15 Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2

Country Status (17)

Country Link
US (2) US5620886A (fr)
EP (1) EP0690675B1 (fr)
JP (1) JP3433322B2 (fr)
CN (1) CN1072719C (fr)
AT (1) ATE258379T1 (fr)
AU (1) AU675707B2 (fr)
CA (1) CA2158446C (fr)
DE (2) DE69433518D1 (fr)
DK (1) DK0690675T5 (fr)
ES (1) ES2210252T3 (fr)
FI (1) FI954360A (fr)
NO (1) NO953601L (fr)
NZ (1) NZ263348A (fr)
PT (1) PT690675E (fr)
TW (1) TW442568B (fr)
WO (1) WO1994021126A1 (fr)
ZA (1) ZA941812B (fr)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5856091A (en) 1993-03-18 1999-01-05 Ludwig Institute For Cancer Research Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
JPH10505481A (ja) * 1994-04-22 1998-06-02 アメリカ合衆国 メラノーマ抗原
US5874560A (en) * 1994-04-22 1999-02-23 The United States Of America As Represented By The Department Of Health And Human Services Melanoma antigens and their use in diagnostic and therapeutic methods
US5997870A (en) * 1994-06-03 1999-12-07 Ludwig Institute For Cancer Research Isolated peptides which bind to HLA-B44 Molecules
US5821122A (en) * 1995-06-07 1998-10-13 Inserm (Institute Nat'l De La Sante Et De La Recherche . .) Isolated nucleic acid molecules, peptides which form complexes with MHC molecule HLA-A2 and uses thereof
UA68327C2 (en) * 1995-07-04 2004-08-16 Gsf Forschungszentrum Fur Unwe A recombinant mva virus, an isolated eukaryotic cell, infected with recombinant mva virus, a method for production in vitro of polypeptides with use of said cell, a method for production in vitro of virus parts (variants), vaccine containing the recombinant mva virus, a method for immunization of animals
US6096313A (en) * 1996-02-09 2000-08-01 Ludwig Institute For Cancer Research Compositions containing immunogenic molecules and granulocyte-macrophage colony stimulating factor, as an adjuvant
FR2746110B1 (fr) * 1996-03-14 1998-04-17 Methode de traitement par therapie genique des tumeurs humaines et virus recombinants correspondants
US5674749A (en) * 1996-03-26 1997-10-07 Ludwig Institute For Cancer Research Monoclonal antibodies which bind to tumor rejection antigen precursor melan-A, and uses thereof
WO1997049817A1 (fr) * 1996-06-25 1997-12-31 The Ludwig Institute For Cancer Research Antigene anticancereux sous forme de phosphorylase agissant sur le glycogene cerebral
WO1998032855A1 (fr) 1997-01-27 1998-07-30 Ludwig Institute For Cancer Research Acides nucleiques lage-1 associes aux tumeurs
US5879892A (en) * 1997-04-25 1999-03-09 Ludwig Institute For Cancer Research Leukemia associated genes
EP1051507A4 (fr) * 1998-01-26 2003-02-05 Genzyme Corp Cellules specifiques d'antigenes, procedes de production et utilisations associes
US7001999B1 (en) * 1998-04-15 2006-02-21 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6245525B1 (en) 1998-07-27 2001-06-12 Ludwig Institute For Cancer Research Tumor associated nucleic acids and uses therefor
US6770456B1 (en) 1998-07-29 2004-08-03 Ludwig Institute For Cancer Research Endogenous retrovirus tumor associated nucleic acids and antigens
DE19913707A1 (de) * 1999-03-26 2000-10-05 Privates Inst Bioserv Gmbh Immunadsorber zur Sepsistherapie
JP2003512057A (ja) 1999-10-19 2003-04-02 ルードヴィッヒ インスティテュート フォー キャンサー リサーチ Ｍａｇｅ−ａ１２抗原ペプチド及びその利用
US20030113919A1 (en) * 2001-08-17 2003-06-19 Aventis Pasteur, Ltd. Immunogenic targets for melanoma
EP1467759A4 (fr) 2002-01-30 2006-05-31 Brigham & Womens Hospital Compositions et methodes associees a tim-3, molecule de surface cellulaire specifique a th1
US7311914B2 (en) * 2002-08-13 2007-12-25 Ludwig Institute For Cancer Research MAGE-A4 antigenic peptides and uses thereof
US7178491B2 (en) * 2003-06-05 2007-02-20 Caterpillar Inc Control system and method for engine valve actuator
AU2005265182B2 (en) * 2004-06-17 2012-06-21 Mannkind Corporation Epitope analogs
US20060159689A1 (en) * 2004-06-17 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
US20060008468A1 (en) * 2004-06-17 2006-01-12 Chih-Sheng Chiang Combinations of tumor-associated antigens in diagnostics for various types of cancers
AU2005326758B2 (en) 2004-06-23 2011-07-14 Board Of Regents Of The University Of Texas System Methods and compositions for the detection of biological molecules using a two particle complex
US20060159694A1 (en) * 2004-12-29 2006-07-20 Chih-Sheng Chiang Combinations of tumor-associated antigens in compositions for various types of cancers
WO2006138568A2 (fr) 2005-06-17 2006-12-28 Mannkind Corporation Immunotherapie multivalente a effet de declenchement et d'amplification, destinee au traitement d'une tumeur cancereuse
EP2371851A3 (fr) * 2005-06-17 2012-08-01 Mannkind Corporation Analogues d'épitopes
EP2385060A3 (fr) 2005-06-17 2012-02-15 Mannkind Corporation Procédés et communications pour susciter des réponses immunes polyvalentes contre des épitopes dominants et sous-dominants exprimés sur des cellules cancéreuses et le stroma tumoral
WO2008039818A2 (fr) 2006-09-26 2008-04-03 Government Of The United States Of America, Represented By The Secretary, Department Of Health And Human Services Récepteurs des cellules t modifiés, et matériaux et méthodes s'y rapportant
EP2152890A1 (fr) * 2007-05-23 2010-02-17 MannKind Corporation Vecteurs multicistroniques et procédés pour leur conception
EP2570137A3 (fr) 2007-11-07 2013-08-21 Celldex Therapeutics, Inc. Anticorps qui se lient à la cellule dendritique et épithéliale 205 (DEC-205)
US20110274723A1 (en) 2009-10-23 2011-11-10 Mannkind Corporation Cancer immunotherapy and method of treatment
WO2011130434A2 (fr) 2010-04-13 2011-10-20 Celldex Therapeutics Inc. Anticorps qui se lient au cd27 humain et utilisations de ceux-ci
SI3151921T1 (sl) 2014-06-06 2019-12-31 Bristol-Myers Squibb Company Protitelesa proti z glukortikoidom induciranim receptorjem za faktor nekroze tumorja(GITR) in njihova uporaba
EP3268037B1 (fr) 2015-03-09 2022-08-31 Celldex Therapeutics, Inc. Agonistes cd27
HRP20230060T1 (hr) 2015-05-29 2023-03-17 Bristol-Myers Squibb Company Antitijela protiv ox40 i njihova primjena
MX2018006072A (es) 2015-11-19 2018-08-01 Squibb Bristol Myers Co Anticuerpos contra receptor de factor de necrosis de tumor inducido por glucocorticoides (gitr) y usos de los mismos.
CN109071665B (zh) 2016-04-18 2022-11-01 塞德斯医疗公司 结合人cd40的激动性抗体及其用途

Family Cites Families (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5342774A (en) * 1991-05-23 1994-08-30 Ludwig Institute For Cancer Research Nucleotide sequence encoding the tumor rejection antigen precursor, MAGE-1
US5487974A (en) * 1992-12-22 1996-01-30 Ludwig Institute For Cancer-Research Method for detecting complexes containing human leukocyte antigen A2 (HLA-A2) molecules and a tyrosinase drived peptide on abnormal cells

Also Published As

Publication number Publication date
FI954360A0 (fi) 1995-09-15
AU6399394A (en) 1994-10-11
CN1072719C (zh) 2001-10-10
AU675707B2 (en) 1997-02-13
FI954360A (fi) 1995-09-15
EP0690675A1 (fr) 1996-01-10
ATE258379T1 (de) 2004-02-15
NZ263348A (en) 1996-06-25
JPH08507693A (ja) 1996-08-20
EP0690675B1 (fr) 2004-01-28
NO953601L (no) 1995-10-31
US5620886A (en) 1997-04-15
CN1093406A (zh) 1994-10-12
PT690675E (pt) 2004-06-30
DE69433518D1 (de) 2004-03-04
CA2158446A1 (fr) 1994-09-29
DE69433518T2 (de) 2004-06-24
ES2210252T3 (es) 2004-07-01
WO1994021126A1 (fr) 1994-09-29
NO953601D0 (no) 1995-09-13
CA2158446C (fr) 2009-01-06
DE69433518T4 (de) 2009-07-23
EP0690675A4 (fr) 1998-12-23
US5854203A (en) 1998-12-29
JP3433322B2 (ja) 2003-08-04
DK0690675T5 (da) 2008-11-17
TW442568B (en) 2001-06-23
DK0690675T3 (da) 2004-06-01

Similar Documents

Publication Publication Date Title
ZA941812B (en) Isolated nucleic acid sequence coding for a tumor rejection antigen precursor processed to at least one tumor rejection antigen presented by HLA-A2
ZA944196B (en) Isolated peptides which form complexes with MHC molecule HLA-C-clone 10 and uses thereof
CA2223694A1 (fr) Molecules d'acide nucleique isolees, peptides formant des complexes avec la molecule du complexe majeur d'histocompatibilite (mhc) hla-a2 et leurs applications
ZA958039B (en) Isolated nucleic acid molecule coding for tumor rejection antigen precursor dage and uses thereof
HUP9801608A2 (hu) A 11. típusú humán papillomavírusból származó L1-fehérjét kódoló szintetikus HPV6/11-L1-hibrid-DNS
EA200200565A1 (ru) Применение клеток, трансфицированных днк, кодирующей лиганд мнс класса ii, и способ получения таких клеток
FI971609A (fi) Menetelmä 4a,5,9,10,11,12-heksahydro-6H-bentsofuro-(3a,3,2-ef)(2)-bentsatsepiinijohdannaisten valmistamiseksi
AU5720498A (en) Chemical synthesis of nucleosides analogs and their incorporation into polynucleotides
TR200002921T2 (tr) Yarı-Sentetik ekteinasidinler
BG101893A (en) Nodulosporic acid derivatives
ES2193241T3 (es) Nuevas n-2-oxo2.3.4.5-tetrajodrp-1h-1,5-benzodiazepin-3-il)-3-amidas.
HK1008228A1 (en) Isolated, truncated nucleic acid molecules which code for gage tumor rejection antigen
NO970030L (no) Isolert nukleinsyresekvens som koder for et tumor-rejeksjonsantigen presentert av HLA-A2
NZ332369A (en) Isolated nucleic acid molecules which code for GAGE tumor rejection antigen, the tumor rejection antigen, and uses thereof
HUT47136A (en) Process for producing cyclic peptides with anticoagulant effect
DE69735583D1 (de) Semisynthetisches verfahren zur herstellung von didemninanalogen
FR2575466B1 (fr) Nouveaux complexes de silicium hexacoordines, leur procede de preparation et leur application
FR2681069B1 (fr) Nouveau procede de preparation de l'hydrocortisone et nouveaux intermediaires.
EP0179412A3 (fr) Composés peptidiques antigènes
EP0232027A3 (fr) Composés N-carboxyalkyle
OA09197A (fr) "Peptides SDK, leur procédé de préparation ainsi que des compositions thérapeutiques en contenant".
EA200000705A1 (ru) Промежуточные соединения и способ синтеза 17-замещенных 16.бета.-арилокси 4-азастероидов
ES8800204A1 (es) Un procedimiento para la preparacion de piridazinilimidazolidinonas
IT1180220B (it) Miscela di composti diastereoisomeri, ottenuti da (-)-5-(1-idrossi-1-metiletil)-2-metil-2-cicloesen-1-one, avente attivita' mucosecretolitica, procedimento per la sua preparazione e composizioni farmaceutiche che la contengono
EP0048532A3 (fr) Sultines, leur procédé de préparation, un procédé de préparation de sulfoxydes, un procédé de préparation de sparsomycine et des composés apparentés